RPRX Royalty Pharma plc

Price (delayed)

$27.27

Market cap

$16.29B

P/E Ratio

15.23

Dividend/share

$0.82

EPS

$1.79

Enterprise value

$21.59B

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
The P/E is 71% lower than the 5-year quarterly average of 52.7 and 60% lower than the last 4 quarters average of 38.4
The company's quick ratio has surged by 60% QoQ
Royalty Pharma's EPS has surged by 142% YoY but it has decreased by 30% QoQ
The net income has soared by 141% YoY but it has contracted by 30% from the previous quarter
Royalty Pharma's gross profit has decreased by 5% YoY and by 4.9% from the previous quarter
The revenue has decreased by 5% YoY and by 4.9% from the previous quarter

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
597.44M
Market cap
$16.29B
Enterprise value
$21.59B
Valuations
Price to book (P/B)
1.65
Price to sales (P/S)
5.47
EV/EBIT
21.95
EV/EBITDA
21.95
EV/Sales
9.64
Earnings
Revenue
$2.24B
EBIT
$983.33M
EBITDA
$983.33M
Free cash flow
$2.62B
Per share
EPS
$1.79
Free cash flow per share
$5.84
Book value per share
$16.51
Revenue per share
$4.99
TBVPS
$35.96
Balance sheet
Total assets
$16.13B
Total liabilities
$6.27B
Debt
$6.14B
Equity
$9.86B
Working capital
$1.44B
Liquidity
Debt to equity
0.62
Current ratio
12.52
Quick ratio
12.48
Net debt/EBITDA
5.39
Margins
EBITDA margin
43.9%
Gross margin
100%
Net margin
35.7%
Operating margin
42%
Efficiency
Return on assets
4.9%
Return on equity
8.1%
Return on invested capital
4.6%
Return on capital employed
6.1%
Return on sales
43.9%
Dividend
Dividend yield
3.01%
DPS
$0.82
Payout ratio
45.8%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
-2.19%
1 week
-2.92%
1 month
-1.23%
1 year
-17.24%
YTD
-2.92%
QTD
-10.21%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.24B
Gross profit
$2.24B
Operating income
$939.4M
Net income
$798.86M
Gross margin
100%
Net margin
35.7%
Royalty Pharma's net margin has surged by 153% YoY but it has decreased by 26% QoQ
The net income has soared by 141% YoY but it has contracted by 30% from the previous quarter
The operating margin has surged by 75% year-on-year but it has declined by 34% since the previous quarter
The operating income has soared by 66% YoY but it has contracted by 37% from the previous quarter

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
P/E
15.23
P/B
1.65
P/S
5.47
EV/EBIT
21.95
EV/EBITDA
21.95
EV/Sales
9.64
Royalty Pharma's EPS has surged by 142% YoY but it has decreased by 30% QoQ
The P/E is 71% lower than the 5-year quarterly average of 52.7 and 60% lower than the last 4 quarters average of 38.4
RPRX's P/B is 41% below its 5-year quarterly average of 2.8 and 8% below its last 4 quarters average of 1.8
RPRX's equity is down by 2.2% since the previous quarter
The P/S is 24% below the 5-year quarterly average of 7.2 and 2.3% below the last 4 quarters average of 5.6
The revenue has decreased by 5% YoY and by 4.9% from the previous quarter

Efficiency

How efficient is Royalty Pharma business performance
The ROA has soared by 158% YoY but it has decreased by 28% from the previous quarter
RPRX's ROE has soared by 145% YoY but it is down by 30% from the previous quarter
Royalty Pharma's return on sales has surged by 100% YoY but it has decreased by 22% QoQ
The ROIC has soared by 92% YoY but it is down by 26% QoQ

Dividends

What is RPRX's dividend history
DPS
$0.82
Dividend yield
3.01%
Payout ratio
45.8%
Recent dividends

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 157% more than its total liabilities
The company's quick ratio has surged by 60% QoQ
The current ratio has surged by 58% since the previous quarter
Royalty Pharma's debt is 38% lower than its equity
The debt to equity has decreased by 15% YoY
Royalty Pharma's debt has decreased by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.